StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

TScan Therapeutics's enterprise value was -$43.27M on Nov 11, 2026, against -$10.49M a year earlier. Over the last 4 years it ranged from -$155.92M to $577.50M, with a median of -$9.55M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$43.27M–
2025Dec 31, 2025-$24.51M-130.5%
2024Dec 31, 2024$80.45M-12.5%
2023Dec 29, 2023$91.95M–
2022Jan 31, 2022-$153.99M–
2021Dec 31, 2021-$155.92M–

More TScan Therapeutics figures

See a number that looks wrong?